Table 2.
Summary of published studies of CYP17 and breast cancer
| CYP17 (A2/A2 versus A1/A1) and breast cancer | |||||||||||
| All cases | Advanced cases | ||||||||||
| Ref | Study design | Race/ethnicity | Age of patients (years) | Age of control individuals (years) | Cases (n) | Advanced cases (n) | OR | 95% CI | OR | 95% CI | HRT use considered? |
| [7*] | Nested case-control | Afro-American, Asian, Latina | 63.0 ± 8.4 | 61.4 ± 8.3 | 174* | 40 | 1.32† | 0.87-2.0 | 2.5† | 1.07-5.94 | No |
| [16] | Case-control | White | <55 | 45-74 | 835 | 24 | 1.17 | 0.92-1.49 | 0.88† | 0.38-2.01 | No |
| [17] | Nested case-control | White | 60.4 ± 11.7 | 60.2 ± 11.5 | 115 | 30 | 0.89 | 0.41-1.95 | 1.39 | 0.26-7.28 | Yes |
| [18] | Case-control | Afro-American | Not given | Not given | 76 | 21 | 1.40† | 0.44-4.38 | 0.6† | 0.1-4.0 | No |
| Latina | 20 | 7 | 1.93† | 0.75-5.01 | 0.2† | 0.0-1.3 | |||||
| White | 27 | 10 | 0.80† | 0.45-1.43 | 1.7† | 0.6-5.1 | |||||
| [19*] | Nested case-control | White | 58.3 ± 7.1‡ | 464 | 107 | 0.91 | 0.61-1.34 | 0.84† | 0.54-1.32 | Yes | |
| [9*] | Case-control | Taiwanese | Not given | Not given | 150 | Not given | 1.28 | 0.73-2.27 | Yes | ||
| [20] | Case-control | White | 59 (27-91) | 20-44 | 510 | 93§ | 0.94 | 0.54-1.65 | 1.38§ | 0.62-3.06 | No |
Ages are expressed as mean ± standard error, mean (range), orrange. *Total cases, not specified by ethnicity;†odds ratio (OR) reflects A1/A2 + A2/A2 combined;‡age not specified by case-control status;§advanced cases over age 55 years.